电邮这篇文章 Safe Use of Systemic Interferons for Multiple Sclerosis Treatment
- 作者: Snegireva I.I.1, Darmostukova M.A.1, Kazakov A.S.1, Lepakhin V.K.1
-
隶属关系:
- Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
- 期: 卷 52, 编号 10 (2019)
- 页面: 863-864
- 栏目: Drugs
- URL: https://ogarev-online.ru/0091-150X/article/view/245514
- DOI: https://doi.org/10.1007/s11094-019-1916-8
- ID: 245514
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
订阅存取
详细
The safety of interferons was assessed by analyzing 499 spontaneous reports in the Russian database from 2015 to 2017. The results led to the conclusion that the safety profile of systemic interferon preparations that are widely used in medical practice to treat multiple sclerosis is defined by data in spontaneous reports for the development of adverse reactions to them or the ineffectiveness of using them.
作者简介
I. Snegireva
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
编辑信件的主要联系方式.
Email: SnegirevaII@expmed.ru
俄罗斯联邦, 8/2 Petrovskii Blvd, Moscow, 127051
M. Darmostukova
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Email: SnegirevaII@expmed.ru
俄罗斯联邦, 8/2 Petrovskii Blvd, Moscow, 127051
A. Kazakov
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Email: SnegirevaII@expmed.ru
俄罗斯联邦, 8/2 Petrovskii Blvd, Moscow, 127051
V. Lepakhin
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Email: SnegirevaII@expmed.ru
俄罗斯联邦, 8/2 Petrovskii Blvd, Moscow, 127051
补充文件
